Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients

Revista Brasileira de Psiquiatria

Volumn 32, Issue 3, 2010, Pages 275-278

  Dutra, Gustavo Pimentel ^a   Ottoni, Gustavo L ^b   Lara, Diogo R ^a   Bogo, Maurício Reis ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Adenosine; Adenosine deaminase; Gene frequency; Polymorphism, restriction fragment length; Schizophrenia

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; GENOMIC DNA; INOSINE; PURINE;

ADULT; ALLELE; ARTICLE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PSYCHOSIS; PURINE METABOLISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA;

ADENOSINE DEAMINASE; ADULT; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 77958504803     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462010005000003     Document Type: Article

References (23)

1. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):617-29.
2. Dunwiddie TV, Mansino SA. The role and regulation of adenosine in central nervous system. Annu Rev Neurosci. 2001;24:31-55. (Pubitemid 32695222)
3. Ferré S. Adenosine-dopamine interactions in ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl). 1997;133(2):107-20.
4. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M.Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388(6643):674-8. (Pubitemid 27366438)
5. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience. 2000;97(1):195-204. (Pubitemid 30195889)
6. Franco R, Casadó V, Ciruela F, Saura C, Mallol J, Canela EI, Lluis C. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol. 1997;52(4):283-94.
7. Hirschhorn R, Yang DR, Israni A. An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA2 Allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover. Ann Hum Genet. 1994;58(Pt 1):1-9. (Pubitemid 24110508)
8. Battistuzzi G, Iudicone P, Santolamazza P, Petrucci R. Activity of adenosine deaminase allelic forms in intact erythrocytes and lymphocytes. Ann Hum Genet. 1981;45(Pt 1):15-9. (Pubitemid 11056284)
9. Bottini N, De Luca D, Saccucci P, Fiumara A, Elia M, Porfirio MC, Lucarelli P, Curatolo P. Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics. 2001;3(2):111-3. (Pubitemid 33738402)
10. Saccucci P, Arpino C, Rizzo R, Gagliano A, Volzone A, Lalli C, Galasso C, Curatolo P. Association of Adenosine deaminase polymorphism with mild mental retardation. J Child Neurol. 2006;21(9):753-6. (Pubitemid 44696723)
11. Rétey JV, Adam M, Honegger E, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA. 2005;102(43):15676-81. (Pubitemid 41528115)
12. Spencer N, Hopkinson DA, Harris H. Adenosine deaminase polymorphism in man. Ann Hum Genet. 1968;32:9-14.
13. Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Trillo S, Montecchi F, Palermo MT, Pascucci T, Puglisi-Allegra S, Reichelt KL, Conciatori M, Baldi A, Keller F. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am J Med Genet. 2000;96(6):784-90.
14. Brunstein MG, Silveira EM Jr, Chaves LS, Machado H, Schenkel O, Belmonte-de-Abreu P, Souza DO, Lara DR. Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment. Neurosci Lett. 2007;414(1):61-4.
15. Ghisolfi ES, Prokopiuk AS, Becker J, Ehlers JA, Belmont-de-Abreu P, Souza DO, Lara DR. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 2002;27(4):629-37.
16. Rimondini R, Ferre S, Ogren SO, Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmachology. 1997;17(2):82-91. (Pubitemid 27326869)
17. Schmidt A, Böhmer AE, Antunes C, Schallenberger C, Porciúncula LO, Elisabetsky E, Lara DR, Souza DO. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009;156(1):163-72.
18. Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry. 2005;66(2):213-9.
19. Stubbs G, Litt M, Lis E, Jackson R, Voth W, Lindberg A, Litt R. Adenosine deaminase activity decreased in autism. J Am Acad Child Psychiatry. 1982;21(1):71-4.
20. Zoroglu SS, Armutcu F, Ozen S, Gurel A, Silvasli E, Yetkin O, Meram I. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004;254(3):143-7. (Pubitemid 39304462)
21. Hettinger JA, Liu X, Holden JJ. The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders. J Autism Dev Disord. 2007;38(1):14-9.
22. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol. 2004;73(6):379-96.
23. Nishino S, Mignot E, Benson KL, Zarcone VP Jr. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 1998;78(3):141-50. (Pubitemid 28266728)